Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2013 Oct;98(10):1492-5.
doi: 10.3324/haematol.2013.094482.

Light chain amyloidosis: the heart of the problem

Giampaolo Merlini  1 , Giovanni Palladini
Affiliations
Editorial

Light chain amyloidosis: the heart of the problem

Giampaolo Merlini et al. Haematologica. 2013 Oct.
No abstract available

PubMed Disclaimer

References

    1. Dinner S, Witteles W, Afghahi A, Witteles R, Arai S, Lafayette R, et al. Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement. Haematologica. 2013;98(10): 1593–9 - PMC - PubMed
    1. Merlini G, Seldin DC, Gertz MA. Amyloidosis: pathogenesis and new therapeutic options. J Clin Oncol. 2011;29(14):1924–33 - PMC - PubMed
    1. Falk RH. Cardiac amyloidosis: a treatable disease, often overlooked. Circulation. 2011;124(9):1079–85 - PubMed
    1. Liao R, Jain M, Teller P, Connors LH, Ngoy S, Skinner M, et al. Infusion of light chains from patients with cardiac amyloidosis causes diastolic dysfunction in isolated mouse hearts. Circulation. 2001;104(14):1594–7 - PubMed
    1. Guan J, Mishra S, Shi J, Plovie E, Qiu Y, Cao X, et al. Stanniocalcin1 is a key mediator of amyloidogenic light chain induced cardiotoxicity. Basic Res Cardiol. 2013;108(5):378. - PMC - PubMed

Publication types